Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 11470

1.

Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer.

McCool R, Fleetwood K, Glanville J, Arber M, Goodall H, Naidoo S.

Value Health. 2018 Oct;21(10):1259-1268. doi: 10.1016/j.jval.2018.03.012. Epub 2018 May 4. Review.

PMID:
30314628
2.

Targeted nonviral gene therapy in prostate cancer.

Altwaijry N, Somani S, Dufès C.

Int J Nanomedicine. 2018 Sep 25;13:5753-5767. doi: 10.2147/IJN.S139080. eCollection 2018. Review.

3.

Prognostic role of platelet to lymphocyte ratio in prostate cancer: A meta-analysis.

Wang J, Zhou X, He Y, Chen X, Liu N, Ding Z, Li J.

Medicine (Baltimore). 2018 Oct;97(40):e12504. doi: 10.1097/MD.0000000000012504. Review.

4.

The impact of perioperative blood transfusion on survival and recurrence after radical prostatectomy for prostate cancer: A systematic review and meta-analysis.

Pushan Z, Manbiao C, Sulai L, Jun L, Ruidong Z, Hanshen Y.

J Cancer Res Ther. 2018 Sep;14(Supplement):S701-S707. doi: 10.4103/0973-1482.193115. Review.

5.

An Integrative Approach to Prostate Cancer.

Abrams DI.

J Altern Complement Med. 2018 Sep/Oct;24(9-10):872-880. doi: 10.1089/acm.2018.0169. Review.

PMID:
30247964
6.

Are localized prostate cancer biomarkers useful in the clinical practice?

Carneiro A, Priante Kayano P, Gomes Barbosa ÁR, Langer Wroclawski M, Ko Chen C, Cavlini GC, Reche GJ, Sanchez-Salas R, Tobias-Machado M, Sowalsky AG, Bianco B.

Tumour Biol. 2018 Sep;40(9):1010428318799255. doi: 10.1177/1010428318799255. Review.

PMID:
30204063
7.

Genetics and biology of prostate cancer.

Wang G, Zhao D, Spring DJ, DePinho RA.

Genes Dev. 2018 Sep 1;32(17-18):1105-1140. doi: 10.1101/gad.315739.118. Review.

PMID:
30181359
9.

Contrast-Enhanced Transrectal Ultrasound in Focal Therapy for Prostate Cancer.

Ashrafi AN, Nassiri N, Gill IS, Gulati M, Park D, de Castro Abreu AL.

Curr Urol Rep. 2018 Aug 28;19(10):87. doi: 10.1007/s11934-018-0836-6. Review.

PMID:
30155585
10.

Primary prostatic extragastrointestinal stromal tumor: a case report and literature review.

You YH, Zhang Y.

J Int Med Res. 2018 Oct;46(10):4343-4349. doi: 10.1177/0300060518791677. Epub 2018 Aug 28. Review.

11.

68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients.

Sanli Y, Sanli O, Has Simsek D, Subramaniam RM.

Nucl Med Commun. 2018 Oct;39(10):871-880. doi: 10.1097/MNM.0000000000000888. Review.

PMID:
30124601
12.

Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.

Isaacsson Velho P, Carducci MA.

Expert Opin Investig Drugs. 2018 Oct;27(10):811-822. doi: 10.1080/13543784.2018.1513490. Epub 2018 Aug 31. Review.

PMID:
30118330
13.

Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes.

Pathania S, Rawal RK.

Eur J Med Chem. 2018 Sep 5;157:503-526. doi: 10.1016/j.ejmech.2018.08.023. Epub 2018 Aug 9. Review.

PMID:
30114661
14.

Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.

Xu L, Pachynski RK.

Curr Urol Rep. 2018 Aug 13;19(10):79. doi: 10.1007/s11934-018-0835-7. Review.

PMID:
30105573
15.

Improving the Specificity of PSA Screening with Serum and Urine Markers.

Kearns JT, Lin DW.

Curr Urol Rep. 2018 Aug 13;19(10):80. doi: 10.1007/s11934-018-0828-6. Review.

PMID:
30105509
16.

Molecular correlates of intermediate- and high-risk localized prostate cancer.

Ye H, Sowalsky AG.

Urol Oncol. 2018 Aug;36(8):368-374. doi: 10.1016/j.urolonc.2017.12.022. Epub 2018 Mar 2. Review.

PMID:
30103901
17.

Introduction to "Molecular drivers of prostate cancer development, progression, and resistance to therapy".

Barbieri CE.

Urol Oncol. 2018 Aug;36(8):367. doi: 10.1016/j.urolonc.2018.06.003. Epub 2018 Jul 29. Review. No abstract available.

PMID:
30064932
18.

Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.

Kim YJ, Kim YI.

Clin Nucl Med. 2018 Oct;43(10):728-734. doi: 10.1097/RLU.0000000000002210. Review.

PMID:
30059428
19.

The emerging role of imaging in prostate cancer secondary screening: multiparametric magnetic resonance imaging and the incipient incorporation of molecular imaging.

Azadi J, Nguyen ML, Leroy A, Macura KJ, Gorin MA, Rowe SP.

Br J Radiol. 2018 Oct;91(1090):20170960. doi: 10.1259/bjr.20170960. Epub 2018 Jul 26. Review.

PMID:
30048145
20.

Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.

Hofman MS, Iravani A, Nzenza T, Murphy DG.

Urol Clin North Am. 2018 Aug;45(3):503-524. doi: 10.1016/j.ucl.2018.03.016. Epub 2018 Jun 15. Review.

PMID:
30031469

Supplemental Content

Loading ...
Support Center